BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/21/2026 3:32:17 AM | Browse: 4 | Download: 0
 |
Received |
|
2026-01-21 00:49 |
|
Peer-Review Started |
|
2026-01-21 05:31 |
|
First Decision by Editorial Office Director |
|
2026-02-02 09:17 |
|
Return for Revision |
|
2026-02-02 09:17 |
|
Revised |
|
2026-02-04 07:31 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-03-05 02:53 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-03-05 10:00 |
|
Articles in Press |
|
2026-03-05 10:00 |
|
Edit the Manuscript by Language Editor |
|
2026-03-10 01:56 |
|
Typeset the Manuscript |
|
2026-08-14 01:28 |
|
Publish the Manuscript Online |
|
2026-08-21 03:32 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Opinion Review |
| Article Title |
Reviving peroxisome proliferator-activated receptors in fatty liver disease: From herbal formula to nuclear receptor targeting
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yasser Fouad, Ebada M Said, Lubna Kamani and Hisham R El-Khayat |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yasser Fouad, Department of Gastroenterology and Endemic Medicine, Faculty of Medicine Minia University, Al-Horria Street, Minia 19111, Egypt. yasserfouad10@yahoo.com |
| Key Words |
Metabolic dysfunction-associated steatotic liver disease; Peroxisome proliferator-activated receptor alpha; Fatty acid oxidation; Inflammation; Traditional Chinese medicine; Lianhe Xiaozhi ointment |
| Core Tip |
The efficacy of single-target therapies is limited by the interconnected metabolic, inflammatory, and gut-derived mechanisms that drive metabolic dysfunction-associated fatty liver disease. According to the study covered in this editorial, the hepatoprotective effects of Lianhe Xiaozhi ointment are mediated through peroxisome proliferator-activated receptor alpha (PPARα), a key metabolic-immune hub. This work offers a systems-based therapeutic framework by improving hepatic fatty acid oxidation, reducing inflammatory signalling, and altering the gut microbiota to raise endogenous PPARα ligands. These results reinforce the gut microbiota-fatty acid-PPARα axis as a promising target for future metabolic dysfunction-associated fatty liver disease interventions and support physiological, multi-level activation of PPARα. |
| Publish Date |
2026-08-21 03:32 |
| Citation |
Fouad Y, Said EM, Kamani L, El-Khayat HR. Reviving peroxisome proliferator-activated receptors in fatty liver disease: From herbal formula to nuclear receptor targeting. World J Gastroenterol 2026; 32(35): 119168
|
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i35/119168.htm |
| DOI |
https://doi.org/10.3748/wjg.119168 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
